Senores Pharmaceuticals Limited IPO Review
Neutral391-391 · Mainboard
✦
Analyst Verdict
Senores Pharmaceuticals Limited IPO
Neutral
IPO at a Glance
Price Band
391-391
Issue Size
582cr
Min. Investment
₹14,858
Opens
2024-12-18
Closes
2024-12-22
Listing
2024-12-28
Category
Mainboard
Key Strengths
✓Expanding manufacturing for sterile injections.
✓Reducing operational debt through funding.
✓Strategic fund allocation to subsidiaries.
✓Focus on growth through acquisitions.
Key Risks
⚠High dependence on borrowed funds.
⚠Regulatory hurdles in manufacturing.
⚠Market volatility impacts growth plans.
⚠Challenges in fund utilization across subsidiaries.
Frequently Asked Questions
Should I apply for Senores Pharmaceuticals Limited IPO?
Based on our analysis, our rating for Senores Pharmaceuticals Limited IPO is: Neutral. Review the full analysis including strengths, risks, and financials on CheckIPO before making a decision.
What are the key risks of Senores Pharmaceuticals Limited IPO?
High dependence on borrowed funds. Regulatory hurdles in manufacturing. Market volatility impacts growth plans.
What are the strengths of Senores Pharmaceuticals Limited IPO?
Expanding manufacturing for sterile injections. Reducing operational debt through funding. Strategic fund allocation to subsidiaries.
What is the price band of Senores Pharmaceuticals Limited IPO?
The price band for Senores Pharmaceuticals Limited IPO is 391-391. The IPO has closed.
Full Analysis Available
Financials, DRHP breakdown, peer comparison, shareholding pattern & more